Literature DB >> 31657665

Uptake of the HPV vaccine among people with and without HIV, cisgender and transgender women and men who have sex with men and with women at two sexual health clinics in Mexico City.

Betania Allen-Leigh1, Leonor Rivera-Rivera1, Elsa Yunes-Díaz2, Alejandra Jalil Portillo-Romero3, Brandon Brown4, Leith León-Maldonado5,6, Galileo Vargas-Guadarrama7, Jorge Salmerón6, Eduardo Cesar Lazcano-Ponce2.   

Abstract

Our aim was to better understand Human Papillomavirus (HPV) vaccine acceptance among Mexican adults including people with and without HIV, cisgender men who have sex with men (MSM) or with women (MSW), cisgender and transgender women. A computer-assisted, self-administered questionnaire was completed by healthcare users and participants recruited through community organizations, and the first dose of the quadrivalent HPV vaccine was offered at no cost at a large sexual health clinic in Mexico City, from May to December 2018. Socio-demographic characteristics and factors associated with HPV vaccine acceptance were analyzed using logistic regression.The sample of 1915 participants included 1341 cisgender men (70.9%, 1247 MSM and 94 MSW), 396 (20.7%) cisgender women and 178 (9.3%) transwomen; 615 people (32.1%) were HIV positive. Uptake of the HPV vaccine was higher in men and transwomen (91.5% and 87%, respectively) than among cisgender women (81.8%; p < .001). Cisgender women (OR 0.43, 95%CI 0.30-0.61, p < .05) were less likely to accept HPV vaccination than men. Married/partnered people were less likely to accept HPV vaccination compared to those who were single (OR 0.70, 95%CI 0.51-0.97). People living with HIV were not significantly more likely to accept HPV vaccination (OR 1.7; 95%CI 0.86-1.61).HPV vaccine acceptance was high among adult Mexican study participants; it may be higher than among other Mexican adults given most of these individuals are engaged in care. Modifications will be needed in national and international recommendations on HPV vaccination in adults if healthcare personnel are to recommend the vaccine to the population groups studied.

Entities:  

Keywords:  HPV vaccine; cisgender women; men who have sex with men; men who have sex with women; people living with HIV; transgender women; uptake

Year:  2019        PMID: 31657665      PMCID: PMC7227620          DOI: 10.1080/21645515.2019.1675456

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  97 in total

1.  HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.

Authors:  Elmar A Joura; Susanne K Kjaer; Cosette M Wheeler; Kristján Sigurdsson; Ole-Erik Iversen; Mauricio Hernandez-Avila; Gonzalo Perez; Darron R Brown; Laura A Koutsky; Eng Hseon Tay; Patricia García; Kevin A Ault; Suzanne M Garland; Sepp Leodolter; Sven-Eric Olsson; Grace W K Tang; Daron G Ferris; Jorma Paavonen; Matti Lehtinen; Marc Steben; Xavier Bosch; Joakim Dillner; Robert J Kurman; Slawomir Majewski; Nubia Muñoz; Evan R Myers; Luisa L Villa; Frank J Taddeo; Christine Roberts; Amha Tadesse; Janine Bryan; Lisa C Lupinacci; Katherine E D Giacoletti; Shuang Lu; Scott Vuocolo; Teresa M Hesley; Richard M Haupt; Eliav Barr
Journal:  Vaccine       Date:  2008-10-16       Impact factor: 3.641

Review 2.  Barriers to quality health care for the transgender population.

Authors:  Tiffany K Roberts; Corinne R Fantz
Journal:  Clin Biochem       Date:  2014-02-19       Impact factor: 3.281

3.  Health beliefs and vaccine costs regarding human papillomavirus (HPV) vaccination among a U.S. national sample of adult women.

Authors:  Adrian Liau; Nathan W Stupiansky; Susan L Rosenthal; Gregory D Zimet
Journal:  Prev Med       Date:  2012-02-09       Impact factor: 4.018

4.  HPV vaccine acceptability in HIV-infected and HIV negative men who have sex with men (MSM) in Ireland.

Authors:  C Sadlier; A Lynam; S O'Dea; S Delamere; M Quinlan; S Clarke; O Sheils; C Bergin
Journal:  Hum Vaccin Immunother       Date:  2016-05-06       Impact factor: 3.452

5.  Health care access and health behaviors among men who have sex with men: the cost of health disparities.

Authors:  David J McKirnan; Steve N Du Bois; Lisa M Alvy; Kyle Jones
Journal:  Health Educ Behav       Date:  2012-04-13

6.  Social Determinants of Health and Human Papillomavirus Vaccination Among Young Adults, National Health Interview Survey 2016.

Authors:  Erika L Thompson; Brittany L Rosen; Sarah B Maness
Journal:  J Community Health       Date:  2019-02

7.  Knowledge of Pap smear, HPV and the HPV vaccine and the acceptability of the HPV vaccine by Thai women.

Authors:  Chuenkamon Charakorn; Sasivimol Rattanasiri; Arb-aroon Lertkhachonsuk; Duangmani Thanapprapasr; Suwicha Chittithaworn; Sarikapan Wilailak
Journal:  Asia Pac J Clin Oncol       Date:  2011-06       Impact factor: 2.601

8.  Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes.

Authors:  Mauricio Hernández-Ávila; Leticia Torres-Ibarra; Margaret Stanley; Jorge Salmerón; Aurelio Cruz-Valdez; Nubia Muñoz; Rolando Herrero; Ignacio F Villaseñor-Ruíz; Eduardo Lazcano-Ponce
Journal:  Hum Vaccin Immunother       Date:  2015-07-25       Impact factor: 3.452

9.  CDC grand rounds: Reducing the burden of HPV-associated cancer and disease.

Authors:  Eileen F Dunne; Lauri E Markowitz; Mona Saraiya; Shannon Stokley; Amy Middleman; Elizabeth R Unger; Alcia Williams; John Iskander
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-01-31       Impact factor: 17.586

10.  Preparing for human papillomavirus vaccine introduction in Kenya: implications from focus-group and interview discussions with caregivers and opinion leaders in Western Kenya.

Authors:  Allison L Friedman; Kelvin O Oruko; Melissa A Habel; Jessie Ford; Jennine Kinsey; Frank Odhiambo; Penelope A Phillips-Howard; Susan A Wang; Tabu Collins; Kayla F Laserson; Eileen F Dunne
Journal:  BMC Public Health       Date:  2014-08-16       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.